A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001 | MicrobiomeTrials
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-06-01Est. Completion: 2028-03-08
Enrollment target: 17 participants
Locations
University of Florida College of Medicine, Jacksonville, Florida, United States
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States
Kellogg Eye Center - University of Michigan, Ann Arbor, Michigan, United States
Casey Eye Institute - OHSU, Portland, Oregon, United States
Retina Foundation of the Southwest, Dallas, Texas, United States
Baylor College of Medicine, Houston, Texas, United States
Other microbiome trials you might be interested in